VICL (Vical Labs) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: N who wrote (522)	1/21/1998 7:06:00 PM
From: N	Read Replies (2) of 1972

Conversation with Alan Engbring, 1/21/98 ÿ -- Allovectin 7 No data have been released yet on melanoma trials. Bigger project than was expected with multicenter trials. So forewent opportunity to present at past Coronado conference. May present at ASCO in May. Expect to move to PIII first half of 1998. Actually two trials have been proposed to FDA for registry ÿ PIII:ÿ control with chemotherapy agent vs. ÿÿÿÿÿÿÿ chemo + Allovectinÿ ÿ PII/PIII: limit participants to those with regional mets, limited to lymph nodes/lungs. No organ mets. ÿ Head and neck: Patient accrual faster than anticipated. ÿ -- Leuvectin. relevant press release in 3rd quarter so didn't ask more. No stage 3-4 adverse side affects. IL2 product quite toxic but much less adverse when injected locally into tumor with Vical's vaccine.ÿ ÿ -- Revascularization application of VICL growth factors. Merck doesn't reveal which selected until they're about to sell something, or, less jokingly, at advanced trials, say PII when milestones are likely to be triggered.ÿ Can only say much of what is currently being published by scientists in this area is similar to what Merck is doing.ÿ ÿÿÿ Regards, Nancyÿ

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next